1. Home
  2. NXGL vs REVB Comparison

NXGL vs REVB Comparison

Compare NXGL & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.57

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.01

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
REVB
Founded
1997
2020
Country
United States
United States
Employees
19
9
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXGL
REVB
Price
$0.57
$1.01
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
105.0K
40.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$50.77
N/A
Revenue Next Year
$46.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.47
52 Week High
$2.89
$3.21

Technical Indicators

Market Signals
Indicator
NXGL
REVB
Relative Strength Index (RSI) 46.97 47.10
Support Level $0.48 $0.99
Resistance Level $0.64 $1.20
Average True Range (ATR) 0.04 0.05
MACD 0.00 0.00
Stochastic Oscillator 43.31 50.77

Price Performance

Historical Comparison
NXGL
REVB

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: